Drugs / Perindopril
Trials 32
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01016886 | Sep 2010 → Sep 2015 | breast cancer, heart failure | University of Alberta | Unknown | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT02651415 | Aug 2016 → Mar 2018 | colorectal cancer | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT02777489 | Feb 2016 → Jan 2017 | obesity disorder | Gene PreDiT | Terminated | No outcome recorded |
| Phase 2 | NCT01948232 | Sep 2013 → Jul 2015 | childhood malignant neoplasm | The Hospital for Sick Children | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00202592 | Nov 2003 → Apr 2010 | hypertensive disorder | Servier | Completed | No outcome recorded |
| Phase 2 | NCT00202553 | Jul 2003 → Dec 2006 | hypertensive disorder | Servier | Completed | No outcome recorded |
| Phase 38 trials | ||||||
| Phase 3 | NCT04591808 | Sep 2021 → Apr 2022 | hyperlipidemia, hypertensive disorder | Servier | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT04980716 | Jun 2021 → Jan 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT04591210 | Jan 2021 → Dec 2024 | COVID-19, cardiovascular disorder | Ottawa Heart Institute Research Corporation | Completed | No outcome recorded |
| Phase 3 | NCT05820880 | May 2019 → Feb 2022 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | Mixed |
| Phase 3 | NCT01583114 | Dec 2011 → Jan 2014 | dilated cardiomyopathy | French National Institute of Health and Medical Research | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT02729441 | Apr 2010 → Aug 2012 | diabetes mellitus, proteinuria | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT00485368 | Jan 2004 → Sep 2006 | Marfan syndrome | Bayside Health | Completed | No outcome recorded |
| Phase 416 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT06341101 | Mar 2024 → Mar 2026 | diastolic heart failure | Maastricht University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT05683301 | Aug 2022 → Aug 2024 | essential hypertension | Centre for Chronic Disease Control, India | Completed | No outcome recorded |
| Phase 4 | NCT04148820 | Nov 2019 → Oct 2021 | myocardial ischemia | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT04023565 | Mar 2019 → Jun 2020 | hypertensive disorder, metabolic syndrome X | Sergey V. Nedogoda | Unknown | No outcome recorded |
| Phase 4 | NCT03738761 | Feb 2018 → Sep 2019 | essential hypertension | KRKA | Completed | No outcome recorded |
| Phase 4 | NCT03393715 | Feb → Jul 2016 | hypertensive disorder, type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02817360 | Feb 2016 → Dec 2025 overdue | heart disorder, type 2 diabetes mellitus | Martin Huelsmann | Recruiting | No outcome recorded |
| Phase 4 | NCT01669434 | Jun 2015 → Nov 2016 | — | University of Nebraska | Completed | Met primary |
| Phase 4 | NCT02213224 | Aug 2014 → Sep 2016 | NAFLD1 | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01819441 | May 2012 → Dec 2016 | cerebrovascular disorder | Yining Huang | Unknown | No outcome recorded |
| Phase 4 | NCT01219413 | Mar 2009 → Jul 2010 | chronic kidney disease, proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| Phase 4 | NCT00402376 | Apr 2007 → ? | heart failure | University Hospital, Strasbourg, France | Terminated | No outcome recorded |
| Phase 4 | NCT00128518 | Oct 2004 → Sep 2010 | hypertensive disorder | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT00122811 | Nov 2000 → Oct 2008 | hypertensive disorder | Imperial College London | Unknown | Missed primary |
| Phase 4 | NCT03921736 | Jan 2000 → Mar 2001 | essential hypertension | Anna Posadzy-Małaczyńska | Completed | No outcome recorded |
| Phase not applicable2 trials · 1 missed | ||||||
| — | NCT07259733 | Jul 2023 → Dec 2026 expected | resistant hypertension | Instituto Dante Pazzanese de Cardiologia | Recruiting | No outcome recorded |
| — | NCT01867047 | Jun 2013 → Jun 2016 | hypotensive disorder | Duke University | Terminated | Missed primary |
| Comparator or background therapy33 trials | ||||||
| Phase 1 | NCT02308202 Comparator | Jan 2012 → Jun 2014 | post-traumatic stress disorder | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01062451 Comparator | May 2009 → Nov 2013 | methamphetamine dependence, substance abuse | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT04588935 Comparator | Jul 2019 → Feb 2023 | female breast carcinoma | State Institution "Republican Scientific and Practical Center" Cardiology, Belarus | Completed | No outcome recorded |
| Phase 2 | NCT03295734 Comparator | May 2018 → Sep 2024 | hypertensive disorder | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02085265 Comparator | Mar 2014 → Feb 2025 | Alzheimer disease | Sunnybrook Health Sciences Centre | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01118520 Comparator | Sep 2011 → Apr 2015 | abdominal aortic aneurysm | Imperial College London | Completed | No outcome recorded |
| Phase 3 | NCT05288400 Comparator | May → Dec 2018 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 3 | NCT03246555 Comparator | Jul 2016 → Aug 2019 | — | Boryung Pharmaceutical Co., Ltd | Completed | Met primary |
| Phase 3 | NCT01556997 Comparator | Feb 2012 → Feb 2013 | essential hypertension | Symplmed Pharmaceuticals LLC | Completed | No outcome recorded |
| Phase 3 | NCT00461903 Comparator | Dec 2007 → Sep 2015 | atrial fibrillation, essential hypertension | Montreal Heart Institute | Completed | No outcome recorded |
| Phase 3 | NCT00145925 Comparator | Jun 2001 → Mar 2008 | type 2 diabetes mellitus | The George Institute | Completed | Mixed |
| Phase 4 | NCT04342351 Comparator | May 2020 → May 2021 | myocardial infarction | RenJi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04330300 Comparator | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT04306627 Comparator | Apr → Oct 2020 | essential hypertension, hyperlipidemia | Yerevan State Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT05535595 Comparator | Nov 2019 → Aug 2021 | hypertensive disorder | Yonsei University | Completed | Met primary |
| Phase 4 | NCT03502031 Comparator | Oct 2018 → Oct 2022 | diabetic kidney disease | James A. Tumlin, MD | Unknown | No outcome recorded |
| Phase 4 | NCT04254042 Comparator | Oct 2018 → May 2019 | hypertensive disorder | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04222686 Comparator | Dec 2017 → Feb 2018 | type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03047538 Comparator | Sep 2017 → Dec 2019 | hyperlipidemia, hypertensive disorder | Charles University, Czech Republic | Withdrawn | No outcome recorded Stop: Business |
| Phase 4 | NCT02742467 Comparator | Jun 2017 → Jun 2018 | hypertensive disorder | University of Abuja | Completed | Met primary |
| Phase 4 | NCT03747978 Comparator | Oct 2016 → May 2017 | hypertensive disorder, type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02710552 Comparator | Apr 2016 → Mar 2019 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02710539 Comparator | Apr 2016 → Mar 2019 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02299310 Comparator | Nov 2014 → Nov 2015 | chronic kidney disease | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02995954 Comparator | Jan 2014 → Dec 2015 | essential hypertension | Guido Iaccarino | Completed | No outcome recorded |
| Phase 4 | NCT01101009 Comparator | Apr 2010 → Nov 2012 | hypertensive disorder | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Completed | No outcome recorded |
| Phase 4 | NCT01295047 Comparator | Jul 2006 → Dec 2007 | Marfan syndrome | Cardiff University | Completed | No outcome recorded |
| Phase 4 | NCT01089452 Comparator | — | hypertensive disorder | Monash University | Withdrawn | No outcome recorded |
| — | NCT05564780 Background | Jan 2023 → Dec 2026 expected | cardiovascular disorder | Chinese Academy of Medical Sciences, Fuwai Hospital | Not yet recruiting | No outcome recorded |
| — | NCT04036409 Background | Aug 2019 → May 2026 overdue | cognitive disorder, hypertensive disorder, ischemic stroke | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| — | NCT00915928 Comparator | Jul 2009 → May 2012 | — | Odense University Hospital | Terminated | No outcome recorded |
| — | NCT00292162 Comparator | Jan 2007 → Jul 2009 | atrial fibrillation, heart failure | NHS Greater Glasgow and Clyde | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-11-20 | XOMA (US) LLC | Results XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial xoma.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-07-17 | Lannett Company, Inc. | LANNETT SIGNS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF AUTHORIZED GENERIC OF HYPERTENSION DRUG, ACEON®PDF Version investorroom.com ↗ |
| 2013-07-03 | XOMA (US) LLC | XOMA Transfers Perindopril Franchise Rights to Symplmed xoma.com ↗ |
| 2012-11-20 | XOMA (US) LLC | XOMA Announces Perindopril and Amlodipine Fixed-Dose Combination Meets Primary Endpoint in Phase 3 PATH Trial xoma.com ↗ |
| 2012-01-17 | XOMA (US) LLC | XOMA Acquires U.S. Rights to Perindopril Franchise and Establishes Commercial Operations xoma.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 67 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Perindopril | “Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC)...” NCT06275763 ↗66“Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ “preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine” NCT04036409 ↗ “The participants in the Treatment group will begin with a single category antihypertensive drug to control their blood pressure, for example, perindopril.” NCT05564780 ↗ “RAAS (Lisinopril, Enalapril, Perindopril, Losartan, and Valsartan taken each day at maximum tolerated dose that will different for each subject)” NCT03502031 ↗ “The study recommends physicians to select an ACEi with proven benefit in cardiovascular diseases such as perindopril, ramipril or enalapril.” NCT04591210 ↗ “free monocomponents of Amlodipine 5 mg, Bisoprolol fumarate 5 mg and Perindopril arginine 5 mg given concomitantly” NCT05288400 ↗ “Benazepril, captopril, enalapril, fosinopril, lisinopril, perindopril, quinapril, ramipril, trandolapril” NCT04330300 ↗ “Fixed-dose combination (FDC) of perindopril/amlodipine, tablets.” NCT03738761 ↗ “Fixed Dose combination of Perindopril/Indapamide/Amlodipine” NCT05820880 ↗ “fosinopril, lisinopril, moexipril, perindopril, quinapril” NCT00684489 ↗ |
| Known as | Aceon | “Examples of possible ACE-I drugs include: benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril),...” NCT01867047 ↗ |
| Known as | Coversyl | “Coversyl (perindopril arginine) 5mg, 1 tablet/day” NCT05288400 ↗1“Coversyl (perindopril)” NCT00485368 ↗ |
| Known as | COVERSYL (perindopril erbumine) or "perindopril" | “COVERSYL (perindopril erbumine) or "perindopril"” NCT02651415 ↗ |
| Known as | PER | “the angiotensin-converting enzyme inhibitor, perindopril (PER)” PMID 24293132 ↗ Nov 2013 |
| Known as | S90625 | “S90625 a Paediatric Formulation of Perindopril” NCT00202592 ↗ |
| Action | Inhibit | “the angiotensin-converting-enzyme (ACE) inhibitor (perindopril 2-4 mg)” PMID 20573778 ↗ Jun 2010 |
| Modality | Small molecule | “the angiotensin-converting-enzyme (ACE) inhibitor (perindopril 2-4 mg)” PMID 20573778 ↗ Jun 2010 |
| Route | Oral | “8 mg/Day Oral Perindopril” NCT00461903 ↗ |
| Target | ACE | “ACE inhibitor” NCT00461903 ↗ |